These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Neurofibromatosis type 1 associated with Charcot-Marie-Tooth type 1A. Koc F; Guzel AI J Dermatol; 2009 May; 36(5):306-11. PubMed ID: 19383003 [TBL] [Abstract][Full Text] [Related]
23. Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A. Yoshikawa H; Nishimura T; Nakatsuji Y; Fujimura H; Himoro M; Hayasaka K; Sakoda S; Yanagihara T Ann Neurol; 1994 Apr; 35(4):445-50. PubMed ID: 7512319 [TBL] [Abstract][Full Text] [Related]
24. Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease. Haberlová J; Seeman P Pediatr Neurol; 2010 Dec; 43(6):407-10. PubMed ID: 21093731 [TBL] [Abstract][Full Text] [Related]
25. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Klein D; Patzkó Á; Schreiber D; van Hauwermeiren A; Baier M; Groh J; West BL; Martini R Brain; 2015 Nov; 138(Pt 11):3193-205. PubMed ID: 26297559 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Sereda MW; Meyer zu Hörste G; Suter U; Uzma N; Nave KA Nat Med; 2003 Dec; 9(12):1533-7. PubMed ID: 14608378 [TBL] [Abstract][Full Text] [Related]
27. Patients homozygous for the 17p11.2 duplication in Charcot-Marie-Tooth type 1A disease. LeGuern E; Gouider R; Mabin D; Tardieu S; Birouk N; Parent P; Bouche P; Brice A Ann Neurol; 1997 Jan; 41(1):104-8. PubMed ID: 9005872 [TBL] [Abstract][Full Text] [Related]
28. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in Charcot-Marie-Tooth disease. Baets J; De Jonghe P; Timmerman V Curr Opin Neurol; 2014 Oct; 27(5):532-40. PubMed ID: 25110935 [TBL] [Abstract][Full Text] [Related]
30. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Verhamme C; van Schaik IN; Koelman JH; de Haan RJ; de Visser M Brain; 2009 Dec; 132(Pt 12):3252-62. PubMed ID: 19843647 [TBL] [Abstract][Full Text] [Related]
32. Charcot-Marie-Tooth type 1A with a pes planovalgus foot type: a case report. Miller JR; McAlister JE J Foot Ankle Surg; 2009; 48(2):208-14. PubMed ID: 19232974 [TBL] [Abstract][Full Text] [Related]
33. [Charcot Marie Tooth disease: exacerbation in pregnancy]. Gastaut JL; Benaim J; Livet MO; Philip N Rev Neurol (Paris); 2000 Oct; 156(10):890-1. PubMed ID: 11033518 [TBL] [Abstract][Full Text] [Related]
34. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456 [TBL] [Abstract][Full Text] [Related]
35. Atypical presentation of Charcot-Marie-Tooth disease 1A: A case report. Kulkarni SD; Sayed R; Garg M; Patil VA Neuromuscul Disord; 2015 Nov; 25(11):916-9. PubMed ID: 26432165 [TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Mandel J; Bertrand V; Lehert P; Attarian S; Magy L; Micallef J; Chumakov I; Scart-Grès C; Guedj M; Cohen D Orphanet J Rare Dis; 2015 Jun; 10():74. PubMed ID: 26070802 [TBL] [Abstract][Full Text] [Related]
37. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. Ichikawa M; Suzuki D; Inamoto J; Ohshima J; Cho Y; Saitoh S; Kaneda M; Iguchi A; Ariga T J Pediatr Hematol Oncol; 2012 Apr; 34(3):239-41. PubMed ID: 22246157 [TBL] [Abstract][Full Text] [Related]
38. Congenital pes cavus in a Charcot-Marie-tooth disease type 1A newborn. Fusco C; Frattini D; Scarano A; Giustina ED Pediatr Neurol; 2009 Jun; 40(6):461-4. PubMed ID: 19433282 [TBL] [Abstract][Full Text] [Related]
39. The role of the prefrontal cortex in the development of muscle fatigue in Charcot-Marie-Tooth 1A patients. Menotti F; Berchicci M; Di Russo F; Damiani A; Vitelli S; Macaluso A Neuromuscul Disord; 2014 Jun; 24(6):516-23. PubMed ID: 24792521 [TBL] [Abstract][Full Text] [Related]
40. De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease. Motley WW; Palaima P; Yum SW; Gonzalez MA; Tao F; Wanschitz JV; Strickland AV; Löscher WN; De Vriendt E; Koppi S; Medne L; Janecke AR; Jordanova A; Zuchner S; Scherer SS Brain; 2016 Jun; 139(Pt 6):1649-56. PubMed ID: 27009151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]